Skip to content

Advertisement

BMC Cancer

Research article
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population

  • Lian-Hua Cui1,
  • Min-Ho Shin2Email author,
  • Sun-Seog Kweon2, 3,
  • Hee Nam Kim4,
  • Hye-Rim Song2,
  • Jin-Mei Piao2,
  • Jin-Su Choi2,
  • Hyun Jeong Shim5,
  • Jun Eul Hwang5,
  • Hyeong-Rok Kim6,
  • Young-Kyu Park6 and
  • Soo-Hyun Kim7
BMC Cancer201010:236

https://doi.org/10.1186/1471-2407-10-236

©  Cui et al; licensee BioMed Central Ltd. 2010

Received: 30 November 2009

Accepted: 26 May 2010

Published: 26 May 2010

Open Peer Review reports

Abstract

Background

This study was designed to investigate an association between the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and the risk of gastric and colorectal cancer in the Korean population.

Methods

We conducted a population-based large-scale case-control study involving 2,213 patients with newly diagnosed gastric cancer, 1,829 patients with newly diagnosed colorectal cancer, and 1,700 healthy controls. Genotyping was performed with peripheral blood DNA for MTHFR C677T polymorphisms. The statistical significance was estimated by logistic regression analysis.

Results

The MTHFR C677T frequencies of CC, CT, and TT genotypes were 35.2%, 47.5%, and 17.3% among stomach cancer, 34%, 50.5%, and 15.5% in colorectal cancer, and 31.8%, 50.7%, and 17.5% in the controls, respectively. The MTHFR 677TT genotype showed a weak opposite association with colorectal cancer compared to the homozygous CC genotype [adjusted age and sex odds ratio (OR) = 0.792, 95% confidence interval (CI) = 0.638-0.984, P = 0.035]. Subjects with the MTHFR 677CT showed a significantly reduced risk of gastric cancer compared whose with the 677CC genotype (age- and sex-adjusted OR = 0.810; 95% CI = 0.696-0.942, P = 0.006). We also observed no significant interactions between the MTHFR C677T polymorphism and smoking or drinking in the risk of gastric and colorectal cancer.

Conclusions

The T allele was found to provide a weak protective association with gastric cancer and colorectal cancer.

Keywords

Gastric CancerColorectal CancerFolate IntakeLock Nucleic AcidMTHFR C677T

Background

Although gastric cancer incidence and mortality have been decreasing around the world, it is still the most common cause of cancer death in Korea for both sexes [1]. Colorectal cancer is very common and has increased rapidly along with the westernization of lifestyle in Korea. Although Helicobacter pylori (H. pylori) strains have been proposed to be a major cause of gastric cancer, they do not provide a complete explanation. Epidemio- logical studies have indicated an association between folate intake and a reduced risk of certain cancers [2–5], including gastric cancer [4] and colorectal cancer [3]. Folate deficiencies may result in abnormal DNA methylation and uncontrolled gene expression leading to malignant transformation [6, 7].

Methylenetetrahydrofolate reductase (MTHFR) is an enzyme that plays an essential role in the metabolism of folic acid and catalyzes the irreversible reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. A change of C to T at nucleotide 677 in MTHFR C677T results in an amino acid substance change of an alanine to valine, and this substance is associated with reduced enzyme activity that leads to reduced plasma folate levels [8]. Low enzyme activity of MTHFR C677T variant genotypes are associated with DNA hypomethylation, which may induce genomic instability and thereby affect the expression of oncogenes or tumor suppressor genes.

The association between the MTHFRC677T gene polymorphisms and genetic susceptibility to stomach cancer and colorectal cancer has been widely evaluated in recent studies, but with controversial conclusions. Several studies reported that a homozygous variant genotype of the polymorphism of MTHFRC677T was associated with an increased risk of gastric cancer [9, 10] and colorectal cancer [11, 12]. However, other studies reported that individuals with the MTHFR 677TT genotype had a decreased risk of colorectal cancer[13], whereas yet others observed no association between the MTHFRC677T genotype and genetic susceptibility to gastric and colorectal cancer [14–17]. Considering the studies provided to date, quite inconsistent results have been reported on the association of MTHFR C677T gene polymorphisms with genetic susceptibility to stomach cancer and colorectal cancer. We designed a large-scale population-based case-control study in Korea to evaluate the potential role of the MTHFR C677T gene polymorphism in gastric and colorectal cancer risk, which would help us to screen, treat, survey, and prevent gastric and colorectal cancer.

Methods

Subjects

The study population consists of 2,213 patients with newly diagnosed gastric cancer, 1,829 patients with newly diagnosed colorectal cancer (colon cancer 833, rectal cancer 996), and 1,700 population-based controls. All enrolled patients were pathologically confirmed by Chonnam National University Hwasun Hospital between April 2004 and June 2008. Cases with secondary or recurrent tumors were excluded. The tumor stages were classified according to the TNM classification, including clinical or pathological TNM stages. Gastric cancer was classified by anatomical site as cardia (C16.0) or non-cardia (C16.1-16.8) and by histological types such as intestinal, diffuse, or mixed type.

The control group(n = 1,700) consisted of participants in the Thyroid Disease Prevalence Study [18], conducted from July 2004 to January 2006 in Yeonggwang and Muan Counties of Jeollanam-do Province and in Namwon City of Jeollabuk-do, Korea. At the time of their peripheral blood collections, all case and control subjects provided their informed consent to participate in this study. This study was approved by the Institutional Review Board of the Chonnam National University Hwasun Hospital in Hwasun, South Korea.

Genotyping

Genomic DNA was extracted from peripheral blood using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's protocol. Genotyping was performed by PCR-RFLP or real-time PCR. The genotyping protocol for PCR-RFLP was adapted from Frosst et al [19]. After HinfI (Takara, Tokyo,Japan) restriction enzyme digestion, samples were run on a 10% polyacrylamide gel (19:1) using Microtitre Array Diagonal Gel Electrophoresis (MADGE; MadgeBio, Grantham and Southampton, UK).

Genotyping by real-time PCR was performed by allelic discrimination, using dual-labeled probes containing locked nucleic acids (LNA), in a real-time polymerase chain reaction (PCR) assay. PCR primers and LNA probes were designed and synthesized by Intergrated DNA Technologies (IDT) (Coralville; City, IA, USA). PCR primers producing a 104-bp amplicon were as follows: forward primer, 5'-CTTTGAGGCTGACCTGAAGC-3' and reverse primer, 5'-TCACAAAGCGGAA GAA TGTG-3'. Dual-labeled LNA hybridization probes were 5'- FAM -ATG GcT ccc-BHQ1- 3' for the C allele and 5'- cy5-cgA CTc cCg C-BHQ2-3' for the T allele (LNA bases are denoted in upper case, single nucleotide polymorphisms are underlined). Real-time PCR was performed using a Rotor-Gene 3000 multiplex system (Corbett Research, Sydney, Australia) in a 10-μL reaction volume containing 200 nM PCR primer, 10-10 nM each probe, 0.5 U f-taq polymerase (Solgent, Daejeon, Korea), and 40 ng of genomic.

Statistical analysis

The statistical significance of the differences between the patient and control groups was estimated by logistic regression analysis. Adjusted odds ratios (OR) were calculated with logistic regression model that controlled for sex and age and are given with 95% confidence intervals (CI). Subjects with the wild type genotypes (MTHFR 677 CC) were considered to be baseline risk. The expected frequency of control genotypes was checked by the Hardy-Weinberg equilibrium test. Interactions of genotype with smoking, alcohol consumption, and age were estimated using the logistic regression model, products of scores for smoking habit (0, never and 1, ever), drinking habit (0, non-drinker and 1, drinker), age (0, ≤ 65 years and 1, >65 years) and genotype (0, CC genotype for reference allele; 1, CT genotype and 2, TT genotype). Subgroup analysis was conducted on anatomical site, histological type, and TNM staging. The subjects for which there was missing data for smoking, drinking, anatomical site, histological type, and TNM staging were excluded in interaction and subgroup analysis related with these variables. All analyses were performed using the Statistical Package for the Social Sciences software version 17.0 (SPSS, Chicago, IL, USA).

Results

The characteristics of the study population are presented in Table 1. The mean age of patients with gastric cancer and colorectal cancer was significantly higher compared with the control group. A statistically significant sex difference was also found between patients with gastric and colorectal cancer and healthy controls, and the control group had more female subjects. The proportion of smokers in gastric cancer cases was higher than that in the controls, but the proportion among colorectal cancer cases was lower than that in the controls. The proportion of drinkers in both cancer groups was lower than that in the controls.
Table 1

General characteristics of subjects

Characteristics

Controls

Gastric cancer

Colorectal cancer

No

1700

2213

1829

Age, mean,years

52.2 ± 14.3

60.2 ± 12.1*

61.9 ± 11.4**

   ≤ 65 years

1321(77.7)

1314(59.4)

985(53.9)

   >65 years

379(22.3)

899(40.6)*

844(46.1)**

Sex

   

   Male

821(48.3)

1510(68.2)

1149(62.8)

   Female

879(51.7)

703(31.8)*

680(37.2)**

Smoking habitat

   

   Never

1000(58.8)

1127(50.9)

1137(62.2)

   Ever

655(38.5)

997(45.1)*

582(31.8)**

   missing

45(2.6)

89(4.0)

110(6.0)

Drinking habitat

   

   Non-drinker

825(48.5)

1198(54.1)

1084(59.3)

   Drinker

833(49.0)

921(41.6)*

623(34.1)**

   Missing

42(2.5)

94(4.3)

122(6.7)

TNM Stage

   

   I

 

1138(51.4)

291(15.9)

   II

 

305(13.8)

547(29.9)

   III

 

290(13.1)

615(33.6)

   IV

 

386(17.4)

230(12.6)

   Unspecified stage

 

94(4.2)

147(8.0)

Tumor site

   

   Gastric cancer

   

Cardiac

 

106(4.8)

 

Non-cardiac

 

2093(94.6)

 

Unspecified site

 

14(0.6)

 

Colorectal cancer

   

   Colon

  

833(45.5)

   rectum

  

996(54.5)

Histological type

   

   Intestinal

 

1286(58.1)

 

   Diffuse

 

561(25.4)

 

   Mixed

 

240(10.8)

 

   Unspecified type

 

126(5.7)

 

The data is expressed as number, percent and mean ± standard deviation.

* Gastric cancer compared with control, p < 0.05;

**Colorectal cancer compared with control, p < 0.05.

Table 2 shows genotype distributions for MTHFR C677T and their adjusted odds ratios and 95% confidence intervals in gastric and colorectal cancer. The distribution of the MTHFR C677T gene polymorphisms in the controls was in Hardy-Weinberg equilibrium. The MTHFR C677T frequencies of CC, CT, and TT genotypes were 35.2%, 47.5%, and 17.3% among gastric cancer, 34%, 50.5%, and 15.5% in colorectal cancer, and 31.8%, 50.7%, and 17.5% in the controls, respectively. The frequencies of the C and T allele were 59.0% and 41.0% among gastric cancer, 59.2% and 40.8% in colorectal cancer, and 57.1% and 42.9% in the controls, respectively. Compared with the CC genotype, the TT genotype was significantly correlated with a reduced risk of colorectal cancer when adjustments were made for age and sex (age- and sex-adjusted OR = 0.792; 95% CI = 0.638-0.984, P = 0.035). Although our results for MTHFR 677TT and gastric cancer risk did not reach statistical significance, the observed trend (overall TT versus CC OR = 0.877; 95% CI = 0.719-1.070) indicates a somewhat protective effect. Whereas the 677CT genotype was significantly associated with a reduced risk of gastric cancer, the age- and sex-adjusted OR was 0.810 (95% CI = 0.696-0.942, P = 0.006).
Table 2

MTHFR C677T genotype distributions and adjusted odds ratio for gastric and colorectal cancer

    

Gastric cancer

Colorectal cancer

MTHFR C677T

Controls

Gastric cancer

Colorectal cancer

OR a (95% CI)

P value

OR a (95% CI)

P value

CC

540(31.8)

778(35.2)

622(34.0)

1

 

1

 

CT

863(50.7)

1052(47.5)

923(50.5)

0.810(0.696-0.942)

0.006

0.923(0.787-1.082)

0.321

TT

297(17.5)

382(17.3)

284(15.5)

0.877(0.719-1.070)

0.195

0.792(0.638-0.984)

0.035

C

1943(57.1)

2608(59.0)

2167(59.2)

1

 

1

 

T

1457(42.9)

1816(41.0)

1491(40.8)

0.915(0.832-1.008)

0.071

0.902(0.814-0.999)

0.047

OR a, odds ratio adjusted for age and sex; CI, confidence interval;

Table 3 shows interaction between MTHFR C677T polymorphisms and smoking and drinking habit and age for gastric and colorectal cancer risk. When we used the MTHFR 677CC genotype as the reference, smoking habit, drinking habit, and age did not modify the association between the MTHFR C677T genotypes and the risk of gastric cancer or colorectal cancer. When results were stratified by anatomical site, histological type, and TNM staging, we observed no statistically significant differences in genotype distribution (Table 4).
Table 3

Interaction between MTHFR C677T polymorphisms and smoking and drinking habit and age for gastric and colorectal cancer risk.

 

CT vs CC*

TT vs CC*

pfor interactiona

 

ORa(95%CI)

ORa(95%CI)

 

gastric cancer

   

   Smoking habit

   

Never

0.874(0.693-1.102

0.984(0.722-1.339)

 

Ever

0.776(0.632-0.952)

0.825(0.630-1.079)

0.680

   Drinking habit

   

Non-drinker

0.801(0.651-0.986)

0.853(0.647-1.124)

 

Drinker

0.827(0.656-1.042)

0.959(0.707-1.299)

0.847

   Age

   

≤ 65 years

0.852(0.711-1.020)

0.921(0.726-1.167)

 

>65 years

0.700(0.529-0.925)

0.765(0.530-1.103)

0.581

colorectal cancer

   

   Smoking habit

   

Never

0.993(0.762-1.293)

0.955(0.670-1.363)

 

Ever

0.851(0.688-1.053)

0.666(0.499-0.888)

0.301

   Drinking habit

   

Non-drinker

0.854(0.689-1.059)

0.712(0.532-0.954)

 

Drinker

0.950(0.735-1.229)

0.878(0.620-1.243)

0.635

   Age

   

≤ 65 years

0.966(0.819-1.211)

0.810(0.620-1.059)

 

>65 years

0.789(0.597-1.043)

0.759(0.525-1.099)

0.361

ORa ,adjusted for age and sex; CC*, CC as reference group

Interactiona was modeled as a product of smoking habit (0, never and 1, ever),

drinking habit (0,non-drinker and 1, drinker), age (0, ≤ 65 years and 1, >65 years) and genotype in score (0, CC genotype for reference allele; 1, CT genotype and 2, TT genotype)

Table 4

Subgroup analysis by TNM stage, tumor site and histological type for the MTHFR C677T polymorphisms.

 

CT vs CC*

TT vs CC*

 

ORa (95%CI)

ORa (95%CI)

Gastric cancer

  

TNM stage

  

I+II

0.810(0.685-0.958)

0.933(0.750-1.161)

III+IV

0.844(0.685-1.040)

0.792(0.597-1.050)

Tumor site

  

Cardiac

0.906(0.569-1.442)

0.967(0.531-1.760)

Non-cardiac

0.811(0.696-0.944)

0.876(0.717-1.070)

Histological type

  

Intestinal

0.815(0.680-0.978)

0.865(0.681-1.099)

Diffuse

0.832(0.672-1.031)

0.868(0.654-1.153)

Mixed

0.827(0.600-1.139)

1.111(0.748-1.652)

Colorectal cancer

  

TNM stage

  

I+II

0.947(0.775-1.158)

0.854(0.652-1.119)

III+IV

0.823(0.679-0.997)

0.667(0.510-0.871)

Tumor site

  

Colon

0.942(0.744-1.146)

0.727(0.553-0.952)

Rectum

0.888(0.636-1.073)

0.855(0.666-1.099)

ORa, adjusted for age and sex; CC*, CC as reference group

Discussion

The current study represents the largest sample (2,213 gastric cancer, 1,829 colorectal cancer, and 1,700 controls) of the Korean population ever used to evaluate the possible association between the MTHFR C677T gene polymorphisms and susceptibility to gastric and colorectal cancer. The T allele was found to provide a weak protective association with gastric and colorectal cancer.

Previous reports on the MTHFR polymorphism and their associations with stomach cancer have been quite inconsistent. Of the published studies, some studies especially in China [20–22], Italy[9], and Mexico[10], found that the MTHFR 677TT genotype was a strong risk factor for gastric cancer, others no association[15–17], and only one suggested a decreased risk[23]. Although our results for MTHFR 677TT and gastric cancer risk did not reach statistical significance, the observed trend (overall TT versus CC OR = 0.877; 95% CI = 0.719-1.070) indicates a somewhat protective effect, whereas the combination of MTHFR 677CT revealed a significant protective association with gastric cancer, the OR of overall CT versus CC was 0.810 (95% CI, 0.696-0.942). In a Mexican population, Galvan-Portillo et al. [23] reported a significant reduction in diffuse gastric cancer risk for the MTHFR 677 TT genotype among individuals with high consumption of folate (OR = 0.23; 95% CI 0.06-0.84) compared to wild-type homozygous and heterozygous genotypes combined. In fact, in other malignancies such as acute lymphocytic leukemia[24, 25], breast cancer[26], and colorectal cancer[27–29], studies have also reported a protective association between the MTHFR 677TT genotype and the risk of some cancer. In addition, Jiang et al. [30] also suggested that individuals with adequate folate status who are homozygous for the MTHFR 677TT polymorphism have reduced the risk of colorectal cancer. Furthermore, Chen, et al. [31] observed that the TT genotype was protective in folate-replete subjects, whereas the combination of TT and low folate status conferred no protection, or even showed an increased risk. These results suggest that the cancer risk associated with MTHFR polymorphisms may exhibit a gene-nutrient interaction that depends on the level of folate intake or plasma folate levels. However, we could not evaluate the gene-nutrient interaction in our study due to a lack of data regarding the plasma folate levels of case group. Although we had information on the plasma folate levels of 1,700 healthy individuals in the control group, which was based on the general population. The median level of plasma folate was 22.7 nmol/L in our controls. Hao et al. [32] reported that the median values of plasma folate were 16.7 nmol/L in South China and 8.4 nmol/L in North China. This implies that Korean populations might have a relatively higher plasma folate level than do Chinese people. It may be partially explained by the dietary habits of Koreans. Rapid economic growth has led to changes in Korean food consumption patterns: consumption of the staple foods such as rice, barley and potatoes has declined, whereas consumption of meat, fruit, vegetables and dairy products has increased. According to Korean National Health and Nutrition Examination Survey report in 1998, 2001 and 2005, increasing trends in daily vegetable consumption were shown in Korea[33]. It has been known that vegetables and fruits are major source of folate. In addition, the frequency of MTHFR TT homozygotes was 17.5% in our 1,700 healthy controls, which was consistent with findings for the control subjects in Japan (17.2%)[34], but was lower than that reported for control subjects in China (31.1-41%)[22, 35]. Compared to Chinese people, the Korean population might have a relatively low frequency of the MTHFR 677TT genotype and a relatively high plasma folate level. This might provide a partial explanation why the MTHFR 677 mutations were found to be protective for gastric and colorectal cancer in our study.

With regard to the MTHFR C677T genotype and the risk of colorectal cancer, although it has been proposed that the MTHFR polymorphism might be involved in the etiology of cancer through regulation of DNA synthesis and repair, some subsequent studies have not provided evidence for their association with colorectal cancer. In a Japanese case-control study of colorectal cancer[36, 37], results showed that the MTHFR C677T polymorphism did not have a role in the development of colorectal cancer. In addition, Zeybek et al. [17] in Turkey, Plaschke et al. [38] in Germany, and Derwinger et al. [14] in Sweden also reported no association between the risk of colorectal cancer and the MTHFR 677TT genotype. However, several studies observed positive associations between the MTHFR 677TT genotypes and increased risk for colorectal cancer. Miao et al. [39] in China and Guerreiro et al[40]in Portugal demonstrated that the MTHFR 677TT presented a increased risk of colorectal cancer. Our study is consistent with a recent meta-analysis that concluded a small but significant protective effect of MTHFR C677T exists against colorectal cancer risk (overall TT versus CC OR = 0.93; 95% CI, 0.89-0.98) for a worldwide population [28].

Considering that heavy drinking and smoking are recognized as risk factors for gastric and colorectal cancer, we included these factors in our study, our findings showed no interactions between the MTHFR C677T polymorphisms and drinking and smoking. With respect to alcohol consumption and MTHFR genotypes, the results were inconsistent. For colorectal risk, earlier studies reported that a protective effect of the MTHFR TT genotype disappeared in those with a high alcohol intake [27, 29]. A recent Chinese study showed a 5-fold increased gastric cancer risk in drinkers with the MTHFR677T/T genotype[41], whereas a Japanese study showed that the MTHFR 677TT genotype reduced esophageal cancer risk among heavy-drinkers[42]. In addition, no interactions were found between the MTHFR C677T polymorphism and alcohol consumption in the risk of gastric cancer [10, 43]. Cigarette smoking may decrease folate in plasma and produce a localized deficiency of folic acid. Boccia et al. [44] observed that ever smokers carrying the MTHFR 677 T allele showed a significant increased risk of gastric cancer. Our results showed no interaction between MTHFR C677T and smoking in the risk of gastric and colorectal cancer. Yang et al. [42] also did not observe any interaction between the effect of the MTHFR C677T polymorphisms on esophageal cancer risk and smoking.

To the best of our knowledge, only two studies have examined the MTHFR polymorphisms and the risk of gastric cancer and colorectal cancer in a Korean population. However, those studies were based on limited sample sizes. One study by Kim et al. [15] involving 133 gastric cancer and 445 controls showed no relationship between the MTHFR genotype and gastric cancer. Another study included 243 colorectal cancer and 225 controls, results from this study showed no relationship between the MTHFR C677T genotype and the overall risk of colorectal cancer, but the T allele was found to be associated with an increased risk of colon cancer and with a somewhat decreased risk of rectal cancer[45]. Our result showed a tendency for lowered colorectal cancer risk in individuals with the MTHFR 677TT genotype and the same tendency was also found in colon and rectal cancer.

The conflicting results regarding the associations between MTHFR C677T polymorphisms and risks for gastric cancer and colorectal cancer may be due to different ethnicities, different subtypes, and differences in regional dietary and local carcinogen exposures. In addition, many previous studies have considered relatively small populations, leading to difficulties in assessing the true statistical significance of the data.

The limitations of our study are that we did not determine serum folate levels or dietary folate intake in the case groups, and we also did not collect the detailed data on the risk factors of gastric cancer and colorectal cancer. Therefore, we cannot add to the debate on the relationship between gene-environment interactions.

Conclusions

The present case-control study in Korea found a protective effect of the MTHFR C677T variant genotype for gastric and colorectal cancer and suggested that the effects of the MTHFR C677T genotype may differ in populations with different levels of folate intake.

Declarations

Authors’ Affiliations

(1)
Department of Public Health, Qingdao University Medical college, Qingdao, China
(2)
Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, South Korea
(3)
Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, South Korea
(4)
Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, South Korea
(5)
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea
(6)
Department of Surgery, Chonnam National University Hwasun Hospital, Hwasun, South Korea
(7)
Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, South Korea

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.View ArticlePubMedGoogle Scholar
  2. Eichholzer M, Luthy J, Moser U, Fowler B: Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. Swiss Med Wkly. 2001, 131 (37-38): 539-549.PubMedGoogle Scholar
  3. La Vecchia C, Negri E, Pelucchi C, Franceschi S: Dietary folate and colorectal cancer. Int J Cancer. 2002, 102 (5): 545-547. 10.1002/ijc.10720.View ArticlePubMedGoogle Scholar
  4. Larsson SC, Giovannucci E, Wolk A: Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology. 2006, 131 (4): 1271-1283. 10.1053/j.gastro.2006.08.010.View ArticlePubMedGoogle Scholar
  5. Larsson SC, Hakansson N, Giovannucci E, Wolk A: Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst. 2006, 98 (6): 407-413.View ArticlePubMedGoogle Scholar
  6. Choi SW, Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr. 2000, 130 (2): 129-132.PubMedGoogle Scholar
  7. Duthie SJ: Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999, 55 (3): 578-592. 10.1258/0007142991902646.View ArticlePubMedGoogle Scholar
  8. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996, 93 (1): 7-9.View ArticlePubMedGoogle Scholar
  9. Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, Bisonni R, Mari D, Floriani I, Catalano V, et al: Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer. 2006, 118 (3): 628-632. 10.1002/ijc.21397.View ArticlePubMedGoogle Scholar
  10. Lacasana-Navarro M, Galvan-Portillo M, Chen J, Lopez-Cervantes M, Lopez-Carrillo L: Methylenetetrahydrofolate reductase 677C > T polymorphism and gastric cancer susceptibility in Mexico. Eur J Cancer. 2006, 42 (4): 528-533. 10.1016/j.ejca.2005.10.020.View ArticlePubMedGoogle Scholar
  11. Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A, Ortiz-Lopez R, Bosques-Padilla F, Calderon-Garciduenas AL, Zarate-Gomez M, Barrera-Saldana HA: 677T mutation of the MTHFR gene in adenomas and colorectal cancer in a population sample from the Northeastern Mexico. Preliminary results. Rev Gastroenterol Mex. 2001, 66 (1): 32-37.PubMedGoogle Scholar
  12. Shannon B, Gnanasampanthan S, Beilby J, Iacopetta B: A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut. 2002, 50 (4): 520-524. 10.1136/gut.50.4.520.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE: The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev. 2005, 14 (5): 1198-1203. 10.1158/1055-9965.EPI-04-0840.View ArticlePubMedGoogle Scholar
  14. Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B: A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer. 2009, 8 (1): 43-48. 10.3816/CCC.2009.n.007.View ArticlePubMedGoogle Scholar
  15. Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, Hwang SG, Ahn JY, Cha KY, Oh D, et al: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res. 2005, 25 (3B): 2249-2252.PubMedGoogle Scholar
  16. Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, Gjessing HK, Ueland PM, Pera G, Sala N, et al: The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydrofolate reductase polymorphisms in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007, 16 (11): 2416-2424. 10.1158/1055-9965.EPI-07-0256.View ArticlePubMedGoogle Scholar
  17. Zeybek U, Yaylim I, Yilmaz H, Agachan B, Ergen A, Arikan S, Bayrak S, Isbir T: Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. Cell Biochem Funct. 2007, 25 (4): 419-422. 10.1002/cbf.1317.View ArticlePubMedGoogle Scholar
  18. Kim HN, Lee IK, Kim YK, Tran HT, Yang DH, Lee JJ, Shin MH, Park KS, Shin MG, Choi JS, et al: Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma. Br J Haematol. 2008, 140 (3): 287-294. 10.1111/j.1365-2141.2007.06893.x.View ArticlePubMedGoogle Scholar
  19. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Heuvel van den LP, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature genetics. 1995, 10 (1): 111-113. 10.1038/ng0595-111.View ArticlePubMedGoogle Scholar
  20. Shen H, Newmann AS, Hu Z, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wang X, Wei Q: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep. 2005, 13 (2): 355-360.PubMedGoogle Scholar
  21. Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, Wang X, Spitz MR, Wei Q: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer. 2001, 95 (5): 332-336. 10.1002/1097-0215(20010920)95:5<332::AID-IJC1058>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
  22. Wang LD, Guo RF, Fan ZM, He X, Gao SS, Guo HQ, Matsuo K, Yin LM, Li JL: Association of methylenetetrahydrofolate reductase and thymidylate synthase promoter polymorphisms with genetic susceptibility to esophageal and cardia cancer in a Chinese high-risk population. Dis Esophagus. 2005, 18 (3): 177-184. 10.1111/j.1442-2050.2005.00492.x.View ArticlePubMedGoogle Scholar
  23. Galvan-Portillo MV, Cantoral A, Onate-Ocana LF, Chen J, Herrera-Goepfert R, Torres-Sanchez L, Hernandez-Ramirez RU, Palma-Coca O, Lopez-Carrillo L: Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT carriers. Eur J Nutr. 2009, 48 (5): 269-76. 10.1007/s00394-009-0010-5.View ArticlePubMedGoogle Scholar
  24. Franco RF, Simoes BP, Tone LG, Gabellini SM, Zago MA, Falcao RP: The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol. 2001, 115 (3): 616-618. 10.1046/j.1365-2141.2001.03140.x.View ArticlePubMedGoogle Scholar
  25. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G: Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA. 1999, 96 (22): 12810-12815. 10.1073/pnas.96.22.12810.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Chou YC, Wu MH, Yu JC, Lee MS, Yang T, Shih HL, Wu TY, Sun CA: Genetic polymorphisms of the methylenetetrahydrofolate reductase gene, plasma folate levels and breast cancer susceptibility: a case-control study in Taiwan. Carcinogenesis. 2006, 27 (11): 2295-2300. 10.1093/carcin/bgl108.View ArticlePubMedGoogle Scholar
  27. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC, Hunter DJ: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996, 56 (21): 4862-4864.PubMedGoogle Scholar
  28. Huang Y, Han S, Li Y, Mao Y, Xie Y: Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet. 2007, 52 (1): 73-85. 10.1007/s10038-006-0082-5.View ArticlePubMedGoogle Scholar
  29. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R: Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997, 57 (6): 1098-1102.PubMedGoogle Scholar
  30. Jiang Q, Chen K, Ma X, Li Q, Yu W, Shu G, Yao K: Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. Cancer Detect Prev. 2005, 29 (2): 146-154. 10.1016/j.cdp.2004.11.004.View ArticlePubMedGoogle Scholar
  31. Chen J, Giovannucci EL, Hunter DJ: MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. J Nutr. 1999, 129 (2S Suppl): 560S-564S.PubMedGoogle Scholar
  32. Hao L, Ma J, Zhu J, Stampfer MJ, Tian Y, Willett WC, Li Z: High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status. J Nutr. 2007, 137 (2): 407-413.PubMedGoogle Scholar
  33. Lee JS, Kim J: Vegetable intake in Korea: data from the Korean National Health and Nutrition Examination Survey 1998, 2001 and 2005. Br J Nutr. 2010, 1-8.Google Scholar
  34. Suzuki T, Matsuo K, Hiraki A, Saito T, Sato S, Yatabe Y, Mitsudomi T, Hida T, Ueda R, Tajima K: Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis. 2007, 28 (8): 1718-1725. 10.1093/carcin/bgm104.View ArticlePubMedGoogle Scholar
  35. Song C, Xing D, Tan W, Wei Q, Lin D: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res. 2001, 61 (8): 3272-3275.PubMedGoogle Scholar
  36. Marugame T, Tsuji E, Inoue H, Shinomiya S, Kiyohara C, Onuma K, Hamada H, Koga H, Handa K, Hayabuchi H, et al: Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. Cancer Lett. 2000, 151 (2): 181-186. 10.1016/S0304-3835(99)00412-7.View ArticlePubMedGoogle Scholar
  37. Matsuo K, Ito H, Wakai K, Hirose K, Saito T, Suzuki T, Kato T, Hirai T, Kanemitsu Y, Hamajima H, et al: One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. Carcinogenesis. 2005, 26 (12): 2164-2171. 10.1093/carcin/bgi196.View ArticlePubMedGoogle Scholar
  38. Plaschke J, Schwanebeck U, Pistorius S, Saeger HD, Schackert HK: Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability. Cancer Lett. 2003, 191 (2): 179-185. 10.1016/S0304-3835(02)00633-X.View ArticlePubMedGoogle Scholar
  39. Miao XP, Yang S, Tan W, Zhang XM, Ye YJ, Lin DX, Wang S: Association between genetic variations in methylenetetrahydrofolate reductase and risk of colorectal cancer in a Chinese population. Zhonghua Yu Fang Yi Xue Za Zhi. 2005, 39 (6): 409-411.PubMedGoogle Scholar
  40. Guerreiro CS, Carmona B, Goncalves S, Carolino E, Fidalgo P, Brito M, Leitao CN, Cravo M: Risk of colorectal cancer associated with the C677T polymorphism in 5,10-methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients. Am J Clin Nutr. 2008, 88 (5): 1413-1418.PubMedGoogle Scholar
  41. Stolzenberg-Solomon RZ, Qiao YL, Abnet CC, Ratnasinghe DL, Dawsey SM, Dong ZW, Taylor PR, Mark SD: Esophageal and gastric cardia cancer risk and folate- and vitamin B(12)-related polymorphisms in Linxian, China. Cancer Epidemiol Biomarkers Prev. 2003, 12 (11 Pt 1): 1222-1226.PubMedGoogle Scholar
  42. Yang CX, Matsuo K, Ito H, Shinoda M, Hatooka S, Hirose K, Wakai K, Saito T, Suzuki T, Maeda T, et al: Gene-environment interactions between alcohol drinking and the MTHFR C677T polymorphism impact on esophageal cancer risk: results of a case-control study in Japan. Carcinogenesis. 2005, 26 (7): 1285-1290. 10.1093/carcin/bgi076.View ArticlePubMedGoogle Scholar
  43. Zhang FF, Terry MB, Hou L, Chen J, Lissowska J, Yeager M, Zatonski W, Chanock S, Morabia A, Chow WH: Genetic polymorphisms in folate metabolism and the risk of stomach cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16 (1): 115-121. 10.1158/1055-9965.EPI-06-0513.View ArticlePubMedGoogle Scholar
  44. Boccia S, Gianfagna F, Persiani R, La Greca A, Arzani D, Rausei S, D'Ugo D, Magistrelli P, Villari P, Van Duijn CM, et al: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and susceptibility to gastric adenocarcinoma in an Italian population. Biomarkers. 2007, 12 (6): 635-644. 10.1080/13547500701546766.View ArticlePubMedGoogle Scholar
  45. Kim DH, Ahn YO, Lee BH, Tsuji E, Kiyohara C, Kono S: Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. Cancer Lett. 2004, 216 (2): 199-205. 10.1016/j.canlet.2004.08.014.View ArticlePubMedGoogle Scholar

    46. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/236/prepub

Copyright

© Cui et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us